| Market Cap | 1.40B | P/E | - | EPS this Y | 16.10% | Ern Qtrly Grth | - |
| Income | -307M | Forward P/E | -4.82 | EPS next Y | -21.80% | 50D Avg Chg | -5.00% |
| Sales | 117M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -11.00% |
| Dividend | N/A | Price/Book | 2.33 | EPS next 5Y | - | 52W High Chg | -47.00% |
| Recommedations | 1.80 | Quick Ratio | 4.35 | Shares Outstanding | 90.86M | 52W Low Chg | 22.00% |
| Insider Own | 41.17% | ROA | -17.42% | Shares Float | 54.39M | Beta | 0.85 |
| Inst Own | 59.84% | ROE | -54.87% | Shares Shorted/Prior | 8.25M/7.68M | Price | 19.14 |
| Gross Margin | 70.09% | Profit Margin | -262.39% | Avg. Volume | 1,091,632 | Target Price | 39.20 |
| Oper. Margin | -293.55% | Earnings Date | May 7 | Volume | 596,945 | Change | -1.90% |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
| Truist Securities | Buy | Mar 25, 24 |
| Wedbush | Outperform | Feb 22, 24 |
| Wedbush | Outperform | Jan 30, 24 |
| Mizuho | Buy | Jan 30, 24 |
| Wedbush | Outperform | Jan 17, 24 |
| Morgan Stanley | Overweight | Nov 13, 23 |
| Cantor Fitzgerald | Overweight | Nov 8, 23 |
| Mizuho | Buy | Oct 3, 23 |
| Cantor Fitzgerald | Overweight | Sep 12, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 10% Owner 10% Owner | Jan 29 | Buy | 21.00 | 15,238,095 | 319,999,995 | 30,061,124 | 01/31/24 |
| Goeltz II Robert C. | Chief Financial Offi.. Chief Financial Officer | Jan 02 | Sell | 20 | 2,004 | 40,080 | 51,831 | 01/04/24 |
| Jaen Juan C. | President President | Jan 02 | Sell | 20.09 | 6,975 | 140,128 | 1,215,265 | 01/04/24 |
| GILEAD SCIENCES, INC. | 10% Owner 10% Owner | Jun 28 | Buy | 19.26 | 1,010,000 | 19,452,600 | 14,823,029 | 06/30/23 |
| Jarrett Jennifer | Chief Operating Offi.. Chief Operating Officer | Jun 22 | Sell | 19.12 | 12,437 | 237,795 | 381,566 | 06/26/23 |
| Jarrett Jennifer | Chief Operating Offi.. Chief Operating Officer | Jun 16 | Sell | 19.35 | 12,563 | 243,094 | 394,003 | 06/16/23 |
| Jarrett Jennifer | Chief Operating Offi.. Chief Operating Officer | Jan 26 | Sell | 23.54 | 1,900 | 44,726 | 414,946 | 01/30/23 |
| Goeltz II Robert C. | Chief Financial Offi.. Chief Financial Officer | Dec 16 | Sell | 30.95 | 2,453 | 75,920 | 11,566 | 12/16/22 |
| Tang Carolyn C. | General Counsel General Counsel | Dec 16 | Sell | 30.95 | 2,523 | 78,087 | 28,584 | 12/16/22 |
| Jarrett Jennifer | Chief Operating Offi.. Chief Operating Officer | Dec 16 | Sell | 30.95 | 16,482 | 510,118 | 147,609 | 12/16/22 |
| Jaen Juan C. | President President | Dec 16 | Sell | 30.95 | 4,436 | 137,294 | 218,258 | 12/16/22 |
| ROSEN TERRY J | Chief Executive Offi.. Chief Executive Officer | Dec 16 | Sell | 30.95 | 13,043 | 403,681 | 242,173 | 12/16/22 |
| Tang Carolyn C. | General Counsel General Counsel | Jun 16 | Sell | 21.57 | 2,922 | 63,028 | 23,909 | 06/21/22 |
| ROSEN TERRY J | Chief Executive Offi.. Chief Executive Officer | Jun 16 | Sell | 21.57 | 8,854 | 190,981 | 227,716 | 06/21/22 |
| Jarrett Jennifer | Chief Operating Offi.. Chief Operating Officer | Jun 16 | Sell | 21.57 | 12,695 | 273,831 | 118,619 | 06/21/22 |
| Jaen Juan C. | President President | Jun 16 | Sell | 21.57 | 4,870 | 105,046 | 210,037 | 06/21/22 |
| Jarrett Jennifer | Chief Operating Offi.. Chief Operating Officer | Mar 16 | Sell | 31.62 | 9,617 | 304,090 | 105,978 | 03/18/22 |